NCT06581055View on ClinicalTrials.gov

A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

November 30, 2024

Primary Completion Date

March 30, 2025

Study Completion Date

March 30, 2025

Conditions
Myelodysplastic Syndromes (MDS)
Interventions
DRUG

Luspatercept

As per COMMANDS Trial (NCT03682536) study protocol

DRUG

Epoetin Alfa

As per COMMANDS Trial (NCT03682536) study protocol

Trial Locations (1)

10040

National Taiwan University Hospital (NTUH), Taipei

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06581055 - A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter